Multiple Myeloma Turkish Prospective Patient Registry (THD-MM-Reg)

July 15, 2023 updated by: Turkish Hematology Association

Multiple Myeloma Patient Registry - Prospective National Multi Center Prospective Study

This is a non-interventional, national, multi center, prospective multiple myeloma registry in Turkey

Study Overview

Status

Recruiting

Conditions

Detailed Description

In this study, approximately from 40 centers 1000 patients will be recruited. All patients will be followed-up till the study end.

All the laboratory results, treatment protocols and responses will be recorded and assessed with EORTC Multiple Myeloma Specific Quality of Life Multiple Myeloma Specific (MY-20) and EORTC Quality of Life-C30 questionnaires.

Study Type

Observational

Enrollment (Estimated)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Turkey
      • Istanbul, Turkey
        • Recruiting
        • Medipol University
        • Contact:
          • Gokme Sevindik

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

All patients diagnosed as multiple myeloma received maximum 2 lines of therapy will be included to this prospective registry.

Description

Inclusion Criteria:

  • Diagnosed as multiple myeloma
  • Patients signed informed consent form
  • Patients received no more then 2 lines of therapy

Exclusion Criteria:

  • Patients below 18 years old

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall Survival
Time Frame: [Time Frame: 5 Years]
Time from the diagnosis to the death
[Time Frame: 5 Years]
Progression Free Survival
Time Frame: [Time Frame: 5 Years]
Time from the initiation of treatment to the death from any cause or progression
[Time Frame: 5 Years]

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Turkish Hematology Association

Investigators

  • Principal Investigator: Omur Gokmen Sevindik, Assoc. Prof., Medipol University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 10, 2020

Primary Completion (Estimated)

December 1, 2024

Study Completion (Estimated)

December 1, 2024

Study Registration Dates

First Submitted

October 27, 2019

First Submitted That Met QC Criteria

October 27, 2019

First Posted (Actual)

October 30, 2019

Study Record Updates

Last Update Posted (Actual)

July 18, 2023

Last Update Submitted That Met QC Criteria

July 15, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • THD-MM-Reg

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Myeloma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe